Full-Time

Senior Director/Vice President

Delivery

Posted on 6/27/2024

Orbital Therapeutics

Orbital Therapeutics

51-200 employees

Develops RNA-based medicines and therapies

Expert

Cambridge, MA, USA

Category
Bioinformatics
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • Ph.D. in Biochemistry, Chemical Engineering, Biology, or related scientific discipline.
  • A proven scientific leader with 10+ years of industry experience.
  • Familiarity with delivery of nucleic acids is required.
  • Experience in moving technology from preclinical to clinical stages.
  • Outstanding teamwork, communication, and interpersonal skills.
  • Team leadership experience with a demonstrated track record of personnel development.
  • Ability to adapt to increasing scope and complexity of work brought on by growth/change and helps others manage through change.
Responsibilities
  • Provide leadership and strategic direction for delivery at Orbital.
  • Lead design and synthesis of novel chemical libraries to enhance delivery of nucleic acids in lipid nanoparticles.
  • Engage with CDMOs to successfully scale lead compounds.
  • Develop with expert scientists virus like particles (VLP) delivery technology.
  • Optimize delivery of nucleic acids using either LNP or VLP delivery technologies.
  • Work closely with IP to assess patentability, develop patent strategy and lead preparation of patent applications & documents.
  • Communicate scientifically rigorous findings and delivery strategy via verbal and written communications, including internal presentations to key stakeholders (e.g. Executive leadership team, Board of Directors) and external presentations.
  • Lead, teach and mentor junior staff to promote a culture of growth and learning.

Orbital Therapeutics focuses on developing RNA-based medicines, specifically targeting areas like vaccines, immunomodulation, and protein replacement. The company utilizes RNA technology along with advanced delivery methods and data science to create a platform for a wide range of therapeutic applications. Unlike many competitors, Orbital Therapeutics does not work with small interfering RNA, allowing it to carve out a unique niche in the genetic medicine space. The goal is to enhance global health by harnessing RNA medicines to treat diseases in innovative ways that were not possible before. Revenue is generated through the sale of these RNA-based therapies to healthcare providers, who then administer them to patients.

Company Size

51-200

Company Stage

Series A

Total Funding

$262.6M

Headquarters

San Francisco, California

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Orbital secured $270 million in Series A financing for RNA medicine development.
  • Advancements in lipid nanoparticles enhance targeted RNA delivery with fewer side effects.
  • AI-driven drug discovery accelerates identification of novel RNA targets.

What critics are saying

  • Increased competition from established pharmaceutical companies in RNA-based medicine.
  • Potential delays in clinical trials due to regulatory scrutiny on RNA therapies.
  • Rapid technological advancements may strain Orbital's R&D financial resources.

What makes Orbital Therapeutics unique

  • Orbital Therapeutics focuses on RNA-based medicines excluding small interfering RNA.
  • The company integrates RNA technology with delivery methods, data science, and automation.
  • Orbital's initial focus includes vaccines, immunomodulation, and protein replacement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

3%

2 year growth

13%
Business Wire
Sep 5th, 2024
Orbital Therapeutics Appoints Anna Dixon as Senior Vice President, Human Resources

Orbital Therapeutics appoints Anna Dixon as senior vice president, human resources.

Business Wire
Sep 3rd, 2024
Orbital Therapeutics Appoints Veteran Biopharma Leader, Ron Philip, as Chief Executive Officer

Orbital Therapeutics appoints veteran biopharma leader, Ron Philip, as chief executive officer.

Business Wire
Apr 27th, 2023
Orbital Therapeutics Secures $270 Million in Series A Financing to Unleash Full Potential of RNA Medicines

Orbital Therapeutics, a company focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease, today ann

Pharmaceutical Technology
Apr 27th, 2023
Orbital raises $270m for advancement of RNA medicines

Orbital is developing an RNA platform that can combine well-known and upcoming RNA technologies and delivery systems.

Phacilitate
Apr 27th, 2023
Orbital Therapeutics Closes $270M Series A Funding

Orbital Therapeutics aims to develop RNA-based therapeutics for various human diseases, including next-generation vaccines, immunomodulation, and protein replacement.

INACTIVE